Vident Advisory LLC Lowers Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Vident Advisory LLC decreased its holdings in Regeneron Pharmaceuticals by 43.9% during the first quarter, owning 2,622 shares valued at approximately $1.66 million after the reduction.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, exceeding expectations, with revenue of $3.68 billion, up 3.6% year-over-year.
• Several brokerages have recently adjusted their ratings and target prices for Regeneron, with an average rating of "Moderate Buy" and a consensus price target of $817.67.

Vident Advisory LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 43.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,622 shares of the biopharmaceutical company's stock after selling 2,055 shares during the period. Vident Advisory LLC's holdings in Regeneron Pharmaceuticals were worth $1,663,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. GAMMA Investing LLC increased its stake in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. Nuveen LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $343,764,000. Pacer Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after purchasing an additional 303,785 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after buying an additional 226,952 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of Regeneron Pharmaceuticals stock traded up $6.16 on Friday, hitting $573.38. The company had a trading volume of 959,753 shares, compared to its average volume of 949,804. The stock has a market capitalization of $60.77 billion, a price-to-earnings ratio of 14.45, a P/E/G ratio of 1.90 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58. The stock has a 50 day moving average of $562.59 and a 200-day moving average of $584.62. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business posted $11.56 EPS. The company's revenue for the quarter was up 3.6% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on REGN shares. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Sanford C. Bernstein boosted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 27th. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.